209 related articles for article (PubMed ID: 20307035)
1. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
Ehlers JP; Spirn MJ; Shah CP; Fenton GL; Baker PS; Regillo CD; Ho AC
Ophthalmic Surg Lasers Imaging; 2010; 41(2):182-9. PubMed ID: 20307035
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
3. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
Farah SE
Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
[TBL] [Abstract][Full Text] [Related]
4. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
[TBL] [Abstract][Full Text] [Related]
5. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
Shah AR; Del Priore LV
Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
[TBL] [Abstract][Full Text] [Related]
6. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab.
Almony A; Mansouri A; Shah GK; Blinder KJ
Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
9. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
11. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
12. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Garg S; Brod R; Kim D; Lane RG; Maguire J; Fischer D
Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
Fong DS; Custis P; Howes J; Hsu JW
Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes.
Tao Y; Jonas JB
Retina; 2010 Oct; 30(9):1426-31. PubMed ID: 20539255
[TBL] [Abstract][Full Text] [Related]
15. [Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration].
Manfreda I; Uhlig CE
Klin Monbl Augenheilkd; 2010 Aug; 227(8):657-8. PubMed ID: 20706974
[No Abstract] [Full Text] [Related]
16. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
Bakri SJ; Couch SM; McCannel CA; Edwards AO
Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab.
Wan MJ; Hooper PL; Sheidow TG
Can J Ophthalmol; 2010 Aug; 45(4):375-80. PubMed ID: 20648087
[TBL] [Abstract][Full Text] [Related]
18. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
Aslankurt M; Aslan L; Aksoy A; Erden B; Cekiç O
Eur J Ophthalmol; 2013; 23(4):553-7. PubMed ID: 23516253
[TBL] [Abstract][Full Text] [Related]
19. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
20. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
